Loading...

AIM AIM IMMUNOTECH INC Expansion Plans 8-K Filing

M MM

M

AIM IMMUNOTECH INC

(AIM)

2025 8-K

Investor Key Opinion

Warrant Exercise Agreement

Warrant Inducement

Equity Agreement Update

Rights Offering Completed

Clinical Study Update

Stock Warrants Update

Corporate Presentation Update

Annual Meeting Results

Note Purchase Agreement

Material Agreement Filed

Equity Offerings

Product Expansion

Warning Notification

Voluntary Delisting

Reverse Stock Split

Stock Delisting

Compliance Plan Accepted

Board Appointment

Clinical Study Approval

Clinical Study Announcement

Clinical Trial Update

Annual Meeting Results

NYSE Compliance Warning

Cash Conservation Plan

Compensation Changes

Bylaws Amendment

Lawsuit Decision

Securities Purchase Agreement

Investment Agreement

Supplementary Data on Early...

Annual Meeting of Stockholders

Open Enrollment for Pancrea...

Agreement with Roswell Park...

Clinical Progress Presentation

Invalid Director Nominations

Conference Call Update

Research Agreement

Equity Distribution Agreement

Agreements with Erasmus Uni...

External Links:

On July 28, 2025, AIM ImmunoTech Inc. reported positive results from a Phase 2 study of its drug Ampligen® combined with AstraZeneca’s Imfinzi® for treating patients with metastatic pancreatic cancer.

AI Assistant

AIM IMMUNOTECH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.